Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR
Xiaojia LIU; Mingxiao YIN; Jingwen DONG; Genxiang MAO; Wenjian MIN; Zean KUANG; Peng YANG; Lu LIU; Na ZHANG; Hongbin DENG.
Acta Pharmaceutica Sinica B
; (6): 3134-3149, 2021.
Artículo
en Inglés
| WPRIM | ID: wpr-922800
Programmed cell death ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) cascade is an effective therapeutic target for immune checkpoint blockade (ICB) therapy. Targeting PD-L1/PD-1 axis by small-molecule drug is an attractive approach to enhance antitumor immunity. Using flow cytometry-based assay, we identify tubeimoside-1 (TBM-1) as a promising antitumor immune modulator that negatively regulates PD-L1 level. TBM-1 disrupts PD-1/PD-L1 interaction and enhances the cytotoxicity of T cells toward cancer cells through decreasing the abundance of PD-L1. Furthermore, TBM-1 exerts its antitumor effect in mice bearing Lewis lung carcinoma (LLC) and B16 melanoma tumor xenograft
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados